Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775) Meeting Abstract
| Authors: | Colombo, N.; Lorusso, D.; Casado Herráez, A.; Santin, A. D.; Colomba, E.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Floquet, A.; Monk, B. J.; Banerjee, S.; Penson, R. T.; Kristeleit, R.; Fabbro, M.; Orlando, M.; Mackay, H.; Jensen, E.; Dutta, L.; Orlowski, R.; Makker, V. |
| Abstract Title: | Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775) |
| Meeting Title: | ESMO Congress 2021 |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2021 Sep 16-21 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-09-01 |
| Start Page: | S729 |
| End Page: | S730 |
| Language: | English |
| ACCESSION: | WOS:000700527701192 |
| DOI: | 10.1016/j.annonc.2021.08.1169 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract #726MO -- Source: Wos |
